FIGURE 7.

PPARγ antagonist, CZD-2, indicates a part of the preventive effects of Z-551 on diet-induced obesity and metabolic disorders in WT mice. 4-week-old male WT mice were acclimated to the HFD for 1 week followed by administration of CZD-2 for 11 weeks. A and B, changes in body weight (A), and epididymal WAT weight (B) in WT mice on the HFD (white) or HFD+CZD-2 (black). C, morphology of epididymal WAT. Scale bars indicate 200 μm. D, mRNA expression levels in epididymal WAT. E, plasma leptin Week 11 after CZD-2 administration. F and G, plasma glucose (F) and insulin (G) in the OGTT Week 10 after CZD-2 administration. H, plasma glucose in the ITT Week 9 after CZD-2 administration. In the OGTT, glucose (1.5 g/kg BW) was orally administered after 6-h fasting. In the ITT, insulin (0.75 unit/kg BW) was intraperitoneally injected. Blood samples were obtained at the indicated times. I and J, plasma TG (I) and FFA (J) Week 10 after CZD-2 administration. All results are expressed as mean ± S.E. (n = 6). *, p < 0.05; **, p < 0.01; n.s., not significant.